Entresto vs Crestor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Crestor | |
|---|---|---|
| Generic name | sacubitril/valsartan | rosuvastatin |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | Statin |
| Treats | Chronic heart failure | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | AstraZeneca |
| Year approved | 2015 | 2003 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $45M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Muscle pain, Headache, Liver problems, Increased blood sugar |
Frequently asked questions
Is Entresto or Crestor better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Crestor (rosuvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Crestor?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Crestor is a Statin made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.